Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the <scp>ISAR‐ABSORB</scp> registry

Abstract

The use of everolimus-eluting BRS in routine clinical practice is associated with high antirestenotic efficacy in patients undergoing angiographic surveillance. Overall clinical outcomes at 12 months are satisfactory though stent thrombosis rates are not insignificant. Further study with longer term follow-up and larger numbers of treated patients is required before we can be sure of the role of these devices in clinical practice.